Miller Edward has filed 25 insider transactions across 1 company since January 2024.
Most recent transaction: a sale of 106 shares of Kalaris Therapeutics, Inc. ($KLRS) on February 21, 2025.
Activity breakdown: 0 open-market purchases and 23 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 21, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 106 | $10.08 | 21,575.0000 | 0 | 0.49% | 0.00% |
| Jan. 23, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 47 | $9.45 | 21,686.0000 | 0 | 0.22% | 0.00% |
| Jan. 23, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 5 | $9.94 | 21,681.0000 | 0 | 0.02% | 0.00% |
| Jan. 10, 2025 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 409 | $0.44 | 499,889.0000 | 0 | 0.08% | 0.00% |
| Dec. 11, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | G | Common Stock | 57549 | $0.00 | 500,298.0000 | 0 | 10.32% | 0.00% |
| Dec. 11, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | G | Common Stock | 57549 | $0.00 | 500,298.0000 | 0 | 13.00% | 0.00% |
| Nov. 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 432 | $0.55 | 500,298.0000 | 0 | 0.09% | 0.00% |
| Nov. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 2272 | $0.86 | 500,730.0000 | 0 | 0.45% | 0.00% |
| Oct. 21, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 635 | $0.78 | 503,768.0000 | 0 | 0.13% | 0.00% |
| Oct. 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 766 | $0.77 | 503,002.0000 | 0 | 0.15% | 0.00% |
| Oct. 3, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 377 | $0.81 | 504,403.0000 | 0 | 0.07% | 0.00% |
| Aug. 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 422 | $0.76 | 504,780.0000 | 0 | 0.08% | 0.00% |
| Aug. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 2323 | $0.73 | 505,202.0000 | 0 | 0.46% | 0.00% |
| July 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 634 | $0.75 | 508,282.0000 | 0 | 0.12% | 0.00% |
| July 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 757 | $0.74 | 507,525.0000 | 0 | 0.15% | 0.00% |
| July 2, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 379 | $0.72 | 508,916.0000 | 0 | 0.07% | 0.00% |
| May 17, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 420 | $0.75 | 509,295.0000 | 0 | 0.08% | 0.00% |
| May 3, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 2311 | $0.80 | 509,715.0000 | 0 | 0.45% | 0.00% |
| April 19, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 626 | $0.75 | 512,783.0000 | 0 | 0.12% | 0.00% |
| April 22, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 757 | $0.75 | 512,026.0000 | 0 | 0.15% | 0.00% |
| April 2, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 368 | $0.77 | 513,409.0000 | 0 | 0.07% | 0.00% |
| Feb. 20, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 385 | $0.70 | 513,777.0000 | 0 | 0.07% | 0.00% |
| Feb. 5, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 8869 | $0.67 | 514,162.0000 | 0 | 1.70% | 0.00% |
| Jan. 23, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 1302 | $0.67 | 523,031.0000 | 0 | 0.25% | 0.00% |
| Jan. 4, 2024 | Kalaris Therapeutics, Inc. | $KLRS | Miller Edward | General Counsel | S | Common Stock | 424 | $0.64 | 524,333.0000 | 0 | 0.08% | 0.00% |